Treatment with the AKT activator (SC79) restored p-AKT levels and cell proliferation in CGR11-knockdown cells, whereas the AKT inhibitor (MK2206) reversed the tumor-promoting effects of CGR11 overexpression (Figures 8A–C). This evidence concerns the gene CGREF1 and neoplasm.